Abstract
High dose rate (HDR) brachytherapy combined with external beam radiation therapy (EBRT), neoadjuvant androgen suppression therapy (NAST) and adjuvant androgen suppression therapy (AAST) (Tri-modality) have been used to treat localized high risk prostate cancer. To define prognostic factors of biochemical relapse free survival (bRFS), an analysis of patients treated with Tri-modality were performed.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have